Regeneron presented positive results for investigational siRNA therapeutic in liver disease: Will REGN hold $887.04 support?

Traders Union
All News
Business & Wealth
Companies
Regeneron stock edges higher to $904.38

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

Viktoras Karapetjanc

09.11.2026

Regeneron presented positive results for investigational siRNA therapeutic in liver disease: Will REGN hold $887.04 support? — Regeneron stock edges higher to $904.38

Regeneron presented positive results for its investigational siRNA treatment in metabolic dysfunction-associated steatotic liver disease at AASLD2026. Shares edge higher on the day, trading at $904.38.

REGN price prediction

24H 0.37%

$959.34

48H 0.57%

$961.26

7D 0.72%

$962.68

1M 19.9%

$1,145.98

3M 45.01%

$1,386.03

6M 45.15%

$1,387.35

12M 37.19%

$1,311.22

Current price: $955.8 4.61 0.48%

Closed 11/13

Daily range 943.11

961.79

Weekly range 898.14

976.29

Loading...

Highlights

Regeneron announced favorable outcomes from its investigational siRNA therapy for metabolic dysfunction-associated steatotic liver disease at AASLD2026 and in the New England Journal of Medicine.
Shares of Regeneron edged higher on the day, trading at $904.38.
Of 110 analysts, 71 rate Regeneron stock a buy while 3 recommend selling, with a median price target of $857.

Regeneron presented positive results for its investigational siRNA therapeutic in metabolic dysfunction-associated steatotic liver disease at AASLD2026. The results were also published by the New England Journal of Medicine. The information was shared directly by the company.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Upside structure holds as RSI approach limits further gains

RSI at 63 is approaching overbought territory, suggesting the recent advance in Regeneron stock may be getting stretched and upside could be limited from here. The price continues to hold above its MA-20, MA-50, and MA-200, which keeps the daily chart structure bullish. The nearest support is the weekly low at $887.04, providing a key level for traders to watch.

Odds favor upside continuation as buyers control the forward view

A close above $975.18 would show buyers are willing to follow through on the latest move. With RSI at 63, the rally is moving toward overbought conditions, indicating the current advance could start to lose steam even as price holds near recent highs. Despite a sustained move lower with a firm trend over the past week, the probability of an upside move over the next five trading days is more than 80%, while the chance of downside is less than 20%. Regeneron stock is expected to trade between $864.96 and $943.79 for the coming trading week. A drop below $887.04 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Earlier, analysts noted that Regeneron's stock was maintaining a bullish technical structure with momentum favoring an upward scenario. The recent positive data release reinforces this outlook, making the $887.04 weekly low a critical support to monitor as the stock trades near overbought territory.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Regeneron Pharmaceuticals

Editor's Picks for You

The great sell-off: Why companies are dumping Bitcoin

By Pavlo Kot
4 hours ago

The great sell-off: Why companies are dumping Bitcoin

Editors' Picks

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

By Pavlo Kot
Yesterday

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Editors' Picks

China’s crypto paradox: A booming market despite the ban?

By Alena Volkova
Yesterday

China’s crypto paradox: A booming market despite the ban?

Editors' Picks

All Editors' Top Picks

Latest Regeneron Pharmaceuticals News

What's behind Regeneron's latest 3.3% stock surge?

By Parshwa Turakhiya
11.11.2026

What's behind Regeneron's latest 3.3% stock surge?

Stocks

#Forecast #Regeneron Pharmaceuticals

Will Regeneron stock break higher as upward price move meets weak momentum?

By Jainam Mehta
20.10.2026

Will Regeneron stock break higher as upward price move meets weak momentum?

Stocks

#Forecast #Regeneron Pharmaceuticals

Regeneron Pharmaceuticals receives EMA committee approval for alternative immunotherapy dosing after stock ends session up 2.2%

By Viktoras Karapetjanc
16.10.2026

Regeneron Pharmaceuticals receives EMA committee approval for alternative immunotherapy dosing after stock ends session up 2.2%

Companies

#Regeneron Pharmaceuticals

All Regeneron Pharmaceuticals News

Pavlo Kot
4 hours ago

The great sell-off: Why companies are dumping Bitcoin

Pavlo Kot
Yesterday

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Alena Volkova
Yesterday

China’s crypto paradox: A booming market despite the ban?

Mikhail Vnuchkov
13.11.2026

Global Microsoft outage: What happened and how serious is it?

Dmytro Kharkov
13.11.2026

Meme stocks vs. memecoins: Same viral frenzy, different endgames

Daria Chernytska
4 min ago

Behavioral Finance: Victor Ricciardi co-edits book on investor behavior and psychology

Yulia Slavina
25 min ago

Quinten Francois: Bitcoin and Ethereum underperform S&P 500 over five years

Eugene Komchuk
25 min ago

Late shorters in bitcoin will face severe consequences, Ivan Liljeqvist warns

Igor Krasulya
29 min ago

Stefan Schubert: Central Stockholm flat prices up to 9 times higher than suburbs

Yaroslav Dmytrenko
1 hour ago

Christopher Jaszczynski: Bitcoin price seen as unchanged over five years

Top News

Mélissa Bac
21 min ago

Nvidia’s post-Huang era begins under growing pressure from Washington

Nvidia’s post-Huang era begins under growing pressure from Washington

Ezequiel Gomes
57 min ago

AI infrastructure stocks lose $4.2T as debt and valuation fears grow

AI infrastructure stocks lose $4.2T as debt and valuation fears grow

Pavlo Kot
4 hours ago

The great sell-off: Why companies are dumping Bitcoin

The great sell-off: Why companies are dumping Bitcoin

Jainam Mehta
20 hours ago

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Sholanke Dele
Yesterday

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

AMD stock faces profit-taking risk as AI momentum builds

Olga Shendetskaya
Now

Eurozone economy outperforms expectations, strengthening case for ECB rate hike

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength threatens a drop to 1.1000

Mykhailo Ihnatenko
Now

Ethereum drops below $2,000: Can ETH recover amid $1.64 billion in crypto liquidations?

Pavlo Kot
Now

Indian authorities raid CoinDCX and Delta Exchange over suspicious crypto transactions

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.